- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schering’s imaging sales fall
Revenues in Schering’s diagnostics business unit fell 6% in 1998, the German contrast agent developer reported last month. The Berlin-based company attributed the fall primarily to exchange-rate effects, while falling contrast media prices also had
Revenues in Scherings diagnostics business unit fell 6% in 1998, the German contrast agent developer reported last month. The Berlin-based company attributed the fall primarily to exchange-rate effects, while falling contrast media prices also had an impact. Diagnostics sales fell particularly hard in the fourth quarter, the company said.
For the year (end-December), Schering posted imaging sales of DM 1.48 billion ($837.5 million), compared with DM 1.58 billion ($892.4 million) in 1997. Of total sales last year, x-ray contrast media accounted for DM 1.08 billion ($613.4 million), while MRI contrast sales totaled DM 388 million ($219.6 million). For the entire company, Schering reported that sales climbed 3% before exchange-rate adjustments to DM 6.42 billion ($3.64 billion), and the company reported 7% growth in net income, to DM 478 million ($270.5 million).
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
